NCT05635357View on ClinicalTrials.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

CompletedOBSERVATIONAL
Enrollment

16,989

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions
Breast Cancer
Interventions
DRUG

Anastrozole

Anastrozole claim is used as the exposure group.

DRUG

Exemestane/Letrozole

Exemestane/Letrozole claim is used as the reference group.

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Rutgers University

OTHER

collaborator

Johns Hopkins University

OTHER

lead

Brigham and Women's Hospital

OTHER